title: Multifunctional drugs with different CNS targets for neuropsychiatric disorders.
abstract: The multiple disease etiologies that lead to neuropsychiatric disorders, such as Parkinson's and Alzheimer's disease, amyotrophic lateral sclerosis, Huntington disease, schizophrenia, depressive illness and stroke, offer significant challenges to drug discovery efforts aimed at preventing or even reversing the progression of these disorders. Transcriptomic tools and proteomic profiling have clearly indicated that such diseases are multifactorial in origin. Further, they are thought to be initiated by a cascade of molecular events that involve several neurotransmitter systems. In response to this complexity, a new paradigm has recently emerged that challenges the widely held assumption that 'silver bullet' agents are superior to 'dirty drugs' in therapeutic approaches aimed at the prevention or treatment of neuropsychiatric diseases. A similar pattern of drug development has occurred in strategies for the treatment of cancer, AIDS and cardiovascular diseases. In this review, we offer an overview of therapeutic strategies and novel investigative drugs discovered or developed in our own and other laboratories, that address multiple CNS etiological targets associated with an array of neuropsychiatric disorders.
authors.affiliation: Department of Pharmaceutical Sciences, Northeastern Ohio Universities College of Pharmacy, Rootstow, Ohio, USA.
authors.forename: Cornelis J
authors.initials: CJ
authors.lastname: Van der Schyf
authors.forename: Werner J
authors.initials: WJ
authors.lastname: Geldenhuys
authors.forename: Moussa B H
authors.initials: MB
authors.lastname: Youdim
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001923:Brain Chemistry / Q000187:drug effects* / Q000235:genetics; D001927:Brain Diseases / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D015394:Molecular Structure; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D018377:Neurotransmitter Agents / Q000819:agonists / Q000096:biosynthesis / Q000235:genetics; D018697:Nootropic Agents / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*
chemical_list: D018377:Neurotransmitter Agents; D018697:Nootropic Agents; D011619:Psychotropic Drugs